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Background: The aim of the present study was to evaluate the effects of glucosamine-chondroitin sulphate combi-
nation on internal derangements of temporomandibular joint in clinical and biochemical manners. 
Material and Methods: This randomized clinical study included 31 cases reporting joint tenderness, in which disc 
displacement was detected on MR imaging. In all patients, synovial fluid sampling was performed under local 
anesthesia. In the study group, the patients were prescribed a combination of 1500 mg glucosamine and 1200 mg 
chondroitin sulphate, while patients in the control group were only prescribed 50 mg tramadol HCl (twice daily) 
for pain control. After 8 weeks, synovial fluid sampling was repeated in the same manner. The levels of pain, 
maximum mouth opening (MMO), synovial fluid IL-1ß, IL-6, TNF-α and PGE2 measured before and after phar-
macological intervention were compared. 
Results: The reduction in pain levels was significant in both groups. There was no significant difference between 
two groups in terms of pain reduction. The improvement in MMO was significant in the study group but it was not 
in the control group. The MMO improvement was significantly higher in the study group compared to the control 
group. In the study group, significant decrease was observed in PGE2 level, while the decreases in IL-1β, IL-6 and 
TNF-α levels were not significant. In the control group, no significant decrease was observed in any of the inflam-
matory cytokines after 8 weeks, moreover IL-1ß and IL-6 levels were increased. Alterations of IL-1ß and IL-6 
levels were significant in study group while TNF-α and PGE2 levels were not, compared to control group.
Conclusions: In conclusion, these results might suggest that glucosamine-chondroitin combination significantly 
increases the MMO and decreases the synovial fluid IL1β and IL6 levels in internal derangements of TMJ com-
pared to tramadol. The modifications of synovial fluid TNF-α and PGE2 levels do not reach statistical significance. 
This combination also provides efficient pain relief in similar level with tramadol, a narcotic analgesic.
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Introduction
Temporomandibular joint (TMJ) disorders become in-
creasingly common in society over years. It has been 
seen that these disorders result from various etiologies 
(1). Degeneration of articular structures causes evolu-
tion of non-inflammatory disorders to inflammatory 
ones. These degenerative states enhance tissue destruc-
tion and joint dysfunction by causing release of inflam-
matory mediators to joint space (2). 
Increased interleukin 1 beta (IL-1ß), interleukin 6 
(IL-6), tumor necrosis factor-alpha (TNF-α) and pros-
taglandin E2 (PGE2) levels in synovial fluid are seen 
in internal derangements of TMJ such as anterior disc 
displacement and osteoarthritis (3-5). In many studies, 
it has been reported that there was an increase in the 
levels of these mediators in inflammatory joint diseases 
(6-8). Also, degeneration in the collagen configuration 
of joint tissues and reduction in the amount of prote-
oglycans are seen in these disorders (2). 
Glucosamine and chondroitin are structural molecules 
of joint cartilage (9). Chondroitin is a glycosaminogly-
can comprising a part of proteoglycan structure of car-
tilage. Glucosamine is an essential glycoprotein that 
is necessary for proteoglycan and glycosaminoglycan 
synthesis (10). There are only two pilot studies concern-
ing use of glucosamine and chondroitin in TMJ disor-
ders (11,12). 
Tramadol is a narcotic analgesic with central activity 
without any anti-inflammatory effect. It is a synthetic 
agent belonging to weak opiates class which has both 
opiate and non-opiate mechanisms of action (13). It 
has been recommended in the management of pain re-
lated to inflammatory joint diseases (e.g. osteoarthritis) 
(14,15). However, to the best of our knowledge, there is 
no study on the use of tramadol HCl in the complaints 
related to TMJ.
The aim of the present randomized clinical study was 
to evaluate the effects of glucosamine chondroitin sul-
phate combination on the internal derangements of tem-
poromandibular joint and also to compare the effects of 
this combination with tramadol, a narcotic analgesic, in 
clinical and biochemical manners.
Material and Method
The study was approved by Institutional Ethics Com-
mittee. All participants were informed in detail and 
signed a consent form. The study was conducted on 
34 women (35 joints) aged 18-40 years (mean age 28.6 
years±6.89) with internal derangement of TMJ includ-
ing Wilkes II or III (16), pain (longer than 4 weeks), and 
limitation in mouth opening who had anterior disc dis-
placement. The patients were included after clinical and 
MRI examinations. The patients who were previously 
treated (any invasive treatment or non-steroidal anti-in-
flammatory drugs) for TMJ complaints were excluded. 
Pain levels of the patients during palpation of TMJ were 
recorded according to a numeric pain scale (0: no pain; 
10: intractable pain) (17). The maximum mouth opening 
(MMO) was measured between the edges of the upper 
and lower central incisors by a millimetric ruler. Con-
scious sedation was performed using 0.1 mg/kg i.v. mi-
dazolam. Auriculotemporal nerve block was performed 
by a 35-gauge needle. The needle was inserted at a point 
just below the earlobe and advanced in an anteriosupe-
rior direction, aiming the posterior aspect of the man-
dibular condyle; then 2 ml of 5% bupivacaine hydro-
chloride (Marcaine, AstraZeneca, Turkey) was injected. 
A 21-gauge needle was inserted to upper joint space via 
superior posterolateral approach (18). In this technique 
first needle puncture is 10 mm anterior to the tragus and 
2 mm inferior to an imaginary line connecting the tra-
gus and the outer corner of the eye. Then, 2 ml of saline 
was injected into the joint space, which was aspirated 
thereafter (Fig. 1). This procedure was repeated for 
ten times to obtain synovial fluid sample as described 
previously by Wake et al. (19) Samples obtained were 
stored at -70°C. The patients were randomly assigned 
into 2 groups. The study group was given a combination 
of 1500 mg glucosamine and 1200 mg chondroitin sul-
phate per day (Lifetime®, Nutritional Specialties, Inc. 
Fig. 1. Injection (a) and aspiration (b) of saline into upper joint space of TMJ.
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California, USA). The control group was only given 50 
mg tramadol HCl twice daily peroral (Contramal, Abdi 
İbrahim, Turkey) for pain relief. The medications were 
given to the patients by one of the researcher and the 
medications were not in their original package. The 
names of the medications were not explained to the 
patients formally. The sampling procedures were per-
formed by another researcher who did not know the 
groups of the patients formally. Moreover; during sec-
ond sampling procedures, the results of the first sam-
plings were masked. After 8 weeks, synovial fluid sam-
ples were obtained in the same manner. In case of blood 
aspiration during synovial fluid sampling, the patient 
was excluded. The IL-1ß, IL-6, TNF-α and PGE2 lev-
els were measured in samples by using Enzyme-Linked 
ImmunoSorbent Assay (ELISA) kit (DIA source Immu-
no Assays S.A. Rue de l’Industrie, Nivelles-Belgium). 
The levels of inflammatory cytokines, pain, and MMO 
between two groups were compared.
All statistical analyses were performed by SPSS for 
Windows version 18.0 software. Mann Whitney U test 
was used to compare measurements without normal 
distribution between groups. Dependent measurements 
such as before-after were compared by paired samples 
t-test and Wilcoxon signed rank tests where appropri-
ate. p<0.05 was considered as statistically significant in 
all tests.
Results
Three subjects were excluded due to blood aspiration 
and 1 due to vertigo owing to tramadol HCL. No other 
adverse effect was observed in either of the groups. In-
flammatory cytokines were detected in all patients in-
cluded. It was observed that IL-1ß level was not signifi-
cantly decreased in the study group (p=0.070), whereas 
it was increased in the control group (p=0.004). IL-6 
level was decreased in the study group, but the dif-
ference did not reach to a statistical significance 
(p=0.063). IL-6 level was increased in the control group, 
however the corresponding increase was not statistically 
significant (p=0.104). TNF-α levels were decreased in 
both groups, which did not reach statistical significance 
(p=0.167 for the study group and p=0.840 for the con-
trol group).  PGE2 level was significantly decreased in 
the study group (p=0.000) but not in the control group 
(p=0.252). It was observed that both agents had signifi-
cant effects on pain reduction (p=0.001 for study group 
and p=0.000 for control group) (Table 1). In terms of pain 
relief, the difference between two groups was not statisti-
cally significant (p=0.770) (Table 2). It was observed that 
glucosamine-chondroitin combination and tramadol had 
significant effect on MMO improvement (p= 0.024 for 
study group, and p= 0.00 for control group) (Table 1). 
The improvement of MMO was significantly higher in 
glucosamine-chondroitin combination group when com-
pared with tramadol group (p=0.000) (Table 2).
 Study Group (n=16) Control Group (n=15) 
 Before After P Before After P 
MMO 28.25±3.84 33.50±3.29 .000 30.07±6.15 31.53±4.90 .064 
Pain 6.75 ± 1.88 3.13 ± 3.12 .001 6.67 ± 2.02 3.33 ± 1.84 .000 
IL-1ȕ 40.09±27.02 29.04±16.29 .070 42.43±16.93 48.71±17.32 .004 
IL-6 51.18±34.28 38.53±27.51 .063 30.93±27.26 37.43±21.21 .104 
TNF-Į 7.61±9.87 4.09± 2.98 .167 7.44±8.45 7.15±5.77 .840 
PGE2 7.35±0.36 6.58±0.67 .000 6.81±0.63 6.51±0.85 .252 
Table 1. Maximum mouth opening (MMO) (mm), pain (numeric scale) and cytokine levels (pg/mL) before 
and after experiment in both groups.
p<0.05 statistically significant.
                             Study Group  
                                   (n=16) 
Control Group 
(n=15)       P 
Pain reduction 
(numeric) -3.63±3.42 -3.33±2.09 0.770 
MMO (mm) 5.25±3.38 1.47±2.83 0.000 
IL-1ȕ (pg/ml) -11,06±22,69 6,27±7,09 0.000 
IL-6 (pg/ml) -12,66±25,22 6,50±14,49 0.010 
TNF-Į (pg/ml) -3,51±9,67 -0,29±5,51 0.260 
PGE2 (pg/ml) -1,17±1,70 -0,30±0,97 0.090 
Table 2. Comparison of two groups in terms of improvement of maximum 
mouth opening (mm), pain reduction (numeric scale) and cytokine levels 
difference (pg/mL).
p<0.05 statistically significant.
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Discussion
In this randomized, double-blinded, controlled clinical 
study, we evaluated the effects of glucosamine-chon-
droitin sulphate combination on synovial fluid IL-1ß, 
IL-6, TNF-α and PGE2 levels in internal derangement 
of TMJ. 
The inflammatory cytokines such as prostaglandins, 
interleukines and TNF-α are potential regulators of os-
teoclastogenesis (20). Increased synovial fluid IL-1ß, 
IL-6 and TNF-α levels, which are important findings 
of inflammation, have been frequently addressed in the 
literature (2,20-22). Kaneyama et al. (22) compared IL-
1ß, IL-6 and TNF-α levels measured in synovial fluid 
of TMJ in 55 patients with osteoarthritis and 5 healthy 
volunteers. Authors found that levels of inflammatory 
mediators were higher in patients with internal derange-
ment compared to healthy individuals. In another study 
by the same authors (21), synovial fluids obtained from 
57 patients with degenerative joint disease were com-
pared to those obtained from 7 healthy individuals. Au-
thors concluded that the inflammatory mediators were 
associated with TMJ abnormalities. In particular, they 
reported that IL-6 plays a major role in the development 
of osteoarthritis. The values of cytokines in the present 
study differ widely from the above mentioned two stud-
ies. It is difficult to clarify the reason while we have 
great hassle to standardize the sampling methods, as-
say methods, and patients (22). The results might be af-
fected by various variables including patients’ age and 
gender distribution, duration and intensity of the TMJ 
diseases, trademark of used ELISA kits etc.
Quinn and Bazan (23) were the first to determine the 
presence of PGE2 in inflamed synovial fluid of TMJ and 
showed a considerable correlation with levels of acute 
synovitis. In our study, these mediators were detected 
in all symptomatic patients with internal derangement 
of TMJ detected on MR imaging. The decrease in the 
levels of these mediators in the synovial fluids of the 
study group indicates the anti-inflammatory effect of 
glucosamine-chondroitin sulphate.
There are many studies suggesting the use of glu-
cosamine and chondroitin in the management of oste-
oarthritis in the literature (24-26). The majority of these 
studies address its use in knee and hip osteoarthritis; 
however, there are only two pilot studies concerning 
TMJ disorders (11,12). In 1988, Shankland et al. (11) 
reported that these molecules decreased the sound and 
pain in TMJs. In that study, a decrease was observed 
in the sound and pain of joints in patients taking glu-
cosamine and chondroitin sulphate but authors sug-
gested that a double-blinded study with NSAI control 
would provide more significant results. In 2001, Nguyen 
et al. (12) reported that glucosamine and chondroitin de-
creased TMJ pain and consumption of other analgesics 
by the patients. In our study, a decrease was detected 
in pain level and synovial fluid IL-1ß, IL-6, TNF-α 
and PGE2 levels in patients using 1500 glucosamine 
and 1200 mg chondroitin.  Moreover, a significant im-
provement in MMO was also observed in patients using 
glucosamine-chondroitin combination. Given that in-
flammatory mediators appear to be related to cartilage 
destruction, it might be suggested that glucosamine and 
chondroitin diminishes cartilage degeneration while ef-
ficiently reducing pain in similar level with tramadol, a 
narcotic analgesic with central activity.
Long-term use of non-steroid anti-inflammatory (NSAI) 
drugs in painful internal derangements of TMJ may re-
sult in severe gastrointestinal complications. Simanek et 
al. (27) noted that glucosamine and chondroitin should be 
considered as a nutritional supplement rather than a drug, 
since they have fewer side effects which can be neglected. 
In a study in which effects of glucosamine and chondroi-
tin sulphate on bovine cartilage culture were evaluated in 
vitro, Chan et al. (28) showed that glucosamine-chondroi-
tin combination decreased matrix metalloproteinase and 
nitric oxide production. In the same experiment, it was 
observed that these molecules inhibited mRNA translo-
cation which would inhibit inflammatory cytokines and 
collagenase production.
Tramadol HCl is a synthetic analgesic with central ac-
tivity, without anti-inflammatory effect, which is used 
in cancer, back pain, neuropathic pain and pain relat-
ed to musculoskeletal disorders such as osteoarthritis 
(13,29). American Pain Society (APS) recommends tra-
madol HCl alone or in combination with acetaminophen 
or NSAI drugs to relieve pain related to osteoarthritis 
(14). In the present study, tramadol HCl was used in the 
control group for pain relief. Pubmed search reveals no 
study evaluating the effects of tramadol HCl in TMJ dis-
orders. In a multi-center, randomized, double-blinded 
study on 1028 patients, Burch et al. (13) compared the 
effects of tramadol HCl with those of placebo in pain 
related to osteoarthritis. It was reported that a dose of 
200 mg tramadol HCl per day caused significant reduc-
tion in pain when compared to placebo. In that double-
blinded study; nausea was observed in 66%, followed 
by constipation in 61%, vertigo in 42%, and sleepiness 
in 29% of the patients. These rates were in accordance 
with the literature in 3 months therapy (30). Tramadol 
has been widely prescribed for over 4 decades in many 
countries with limited evidence of dependence and 
abuse. It may be effective in alleviating spontaneous 
opioid withdrawal, although doses higher than those 
typically prescribed for analgesia may be required (31). 
In our study, one patient was excluded who failed to use 
tramadol due to vertigo. In patients using 100 mg tra-
madol HCl, an insignificant increase in IL-1ß and IL-6 
levels, and an insignificant decrease in TNF-α and PGE2 
levels were observed, which confirmed tramadol’s cen-
tral analgesic utility with no anti-inflammatory effect.
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In conclusion, these results might suggest that glu-
cosamine-chondroitin combination significantly in-
creases the MMO and decreases the synovial fluid 
IL1β and IL6 levels in internal derangements of TMJ 
compared to tramadol. In the glucosamine-chondroitin 
combination group, the modifications of synovial fluid 
TNF-α and PGE2 levels do not reach statistical signifi-
cance compared to tramadol group. This combination 
also provides efficient pain relief in similar level with 
tramadol, a narcotic analgesic. As a nutritional supple-
ment with little side effects compared to NSAI or nar-
cotics, glucosamine-chondroitin combination might be 
considered as an adjunctive agent in the treatment of 
internal derangements of TMJ.
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